Xsensio

Xsensio is a wearable biosensor technology company that develops the Lab-on-Skin sensing platform, a highly-miniaturized chip-based system for continuous, real-time biochemical monitoring from the surface of the skin. Developed at the Nanolab of the Swiss Federal Institute of Technology (EPFL), the platform leverages semiconductor properties to collect biochemical information by analyzing electrolytes, metabolites, small molecules, and proteins, unleashing new possibilities in continuous health monitoring. Xsensio's first product focuses on early detection of organ dysfunction, addressing high-impact challenges in critical care, oncology, and post-surgical recovery by enabling earlier detection of clinical deterioration from ICU settings to outpatient care and the home. The Lab-on-Skin platform provides a single sensing architecture supporting many applications, backed by strong IP and leading clinical collaborations. The company has announced a long-term collaboration with Texas Instruments and was listed as one of TIME Magazine's World's Top HealthTech Companies 2025. Founded in 2014 and headquartered in Lausanne, Switzerland, Xsensio has raised $11.6M in Series A funding from investors including DART Ventures, Venture Kick, MassChallenge, FIT, Mayo Clinic, EIC Fund, Privilege Ventures, Europa, WI Harper Group, European Innovation Council, Swisscom StartUp Challenge, and Swiss ICT Investor Club.